Julie M. Reed, the new executive director of the Biosimilars Forum, talks about her experiences working with some of the biggest names in the biosimilars space and what she's taking with her into her new role.
Julie M. Reed, the new executive director of the Biosimilars Forum, talks about her experiences working with some of the biggest names in the biosimilars space and what she's taking with her into her new role.
Transcript:
How has your work with Pfizer, Hospira, and Coherus Biosciences shaped your approach to biosimilars during your time at the Forum?
Reed: I'm probably one of the luckiest people in the world to have worked for those companies and to see the evolution. First of all with Hospira, to be a spearhead in creating and driving with our other members to see that the biosimilars pathway is here, not just in the US but in other regions around the world. So, that has been incredible. And to work on the regulations when I was with Hospira--the regulations we see today were not even written. So, from being part of that conversation and helping to develop the foundation of this marketplace has been incredible.
Coherus Biosciences, that was a great experience in that Coherus, with Udenyca [bevacizumab biosimilar], the scientists at Coherus and the team, to having a small startup mentality, the proactiveness [of the compnay], and Dennis M. Lanfear, the CEO of Coherus and one of my favorite people, and in their physicians are incredible. To have the Udenyca biosimilar launch and for them to lead the science of the analytics on that biosimilar and to evolve that so that biosimilars can be developed without clinical trials is massive. They are so innovative and so scientifically grounded and everything. It was great.
And then, to come to Pfizer, they're leaders in biosimilars they understand and believe that market competition is the way to lower costs and biosimilars are awaiting to have lower costs, have free market competition, have greater access. At the same time, they balance their innovative portfolio and they're focused on patients. And so, Pfizer is an incredible company. So, I think I'm pretty lucky to be where I've been and have what I've learned from all these great companies and just be in this space. It's true. I just feel that way.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.